
This report provides a guide to selecting high-quality commercial antibodies against TRIM21 for use in Western blot, immunoprecipitation, and immunofluorescence, utilizing a standardized experimental protocol that compares readouts in knockout cell lines and isogenic parental controls. This work was supported by the Quebec Consortium for Drug Discovery (CQDM), a grant from the Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec. RA is supported by a Mitacs fellowship.
antibody characterization, western blot, Tripartite motif-containing protein 21, P19474, antibody validation, immunofluorescence, immunoprecipitation, TRIM21, E3 ubiquitin-protein ligase TRIM21
antibody characterization, western blot, Tripartite motif-containing protein 21, P19474, antibody validation, immunofluorescence, immunoprecipitation, TRIM21, E3 ubiquitin-protein ligase TRIM21
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
